Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H6NO3.Mg |
| Molecular Weight | 280.5171 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=JQAACYUZYRBHGG-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Mg/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H6NO3 |
| Molecular Weight | 128.106 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3271 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2111421 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date2012 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii. | 2002 |
|
| Characterizing degradation products of peptides containing N-terminal Cys residues by (off-line high-performance liquid chromatography)/matrix-assisted laser desorption/ionization quadrupole time-of-flight measurements. | 2003 |
|
| Determination of the post-translational modifications of salivary acidic proline-rich proteins. | 2003 Apr |
|
| Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin. | 2003 Apr |
|
| Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. | 2003 Aug 15 |
|
| Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1. | 2003 Aug 19 |
|
| Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors. | 2003 Aug 7 |
|
| Pressure/temperature combined treatments of precursors yield hormone-like peptides with pyroglutamate at the N terminus. | 2003 Dec 31 |
|
| Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana. | 2003 Feb 28 |
|
| Isolation and identification of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale. | 2003 Jan 1 |
|
| [Neuroprotective properties of pyroglutamic acid in combination with pyrrolidone]. | 2003 Jan-Feb |
|
| Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus. | 2003 Jul |
|
| Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues. | 2003 Jul 7 |
|
| 2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation. | 2003 Jun 7 |
|
| Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator. | 2003 Mar |
|
| [Evolution of the neuroprotection concept]. | 2003 Mar-Apr |
|
| [Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism]. | 2003 May |
|
| Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation. | 2003 May |
|
| [Characteristics of pyrrolidone pharmacokinetics in rats]. | 2003 Nov-Dec |
|
| Structural characterization of native mouse zona pellucida proteins using mass spectrometry. | 2003 Sep 5 |
|
| Origin of diastereoselection in the hydrosilylation of chiral N-acyliminium intermediates derived from pyroglutamic acid. | 2004 Apr 26 |
|
| Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
| Glutamine in commercial liquid nutritional products. | 2004 Aug 11 |
|
| Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
| Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies. | 2004 Feb |
|
| Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells. | 2004 Feb |
|
| Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
| Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. | 2004 Feb 24 |
|
| N-acetylation of the glutamate residue of intact glutathione conjugates in rats: a novel pathway for the metabolic processing of thiol adducts of xenobiotics. | 2004 Jan |
|
| Integrative annotation of 21,037 human genes validated by full-length cDNA clones. | 2004 Jun |
|
| Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections. | 2004 Mar |
|
| Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid. | 2004 Mar |
|
| Synthesis of (2S,3S)-3'-fluoroisoleucine. | 2004 Mar 7 |
|
| Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures. | 2004 Mar-Apr |
|
| Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein. | 2004 May 25 |
|
| Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline. | 2004 May 7 |
|
| Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. | 2004 May-Jun |
|
| Discrepin, a new peptide of the sub-family alpha-ktx15, isolated from the scorpion Tityus discrepans irreversibly blocks K+ -channels (IA currents) of cerebellum granular cells. | 2004 Oct 15 |
|
| Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. | 2004 Oct 19 |
|
| Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. | 2004 Sep |
|
| Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). | 2004 Sep |
|
| Mass spectrometry analysis of recombinant human ZP3 expressed in glycosylation-deficient CHO cells. | 2004 Sep 28 |
|
| Nanoparticles on the basis of highly functionalized dextrans. | 2005 Aug 3 |
|
| Physiological and pathological aspects of GSH metabolism. | 2005 Feb |
|
| Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid). | 2005 Jul |
|
| The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. | 2005 Jul 1 |
|
| Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. | 2005 Nov 4 |
|
| Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
|
| Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.). | 2005 Sep 25 |
|
| CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts. | 2006 Feb |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:22 GMT 2025
by
admin
on
Mon Mar 31 18:32:22 GMT 2025
|
| Record UNII |
V5PC588N7G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12CC08
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
||
|
WHO-ATC |
A12CC08
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MAGNESIUM PIDOLATE
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
DBSALT002689
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL397976
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
14559042
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
100000089075
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
116240
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
4597
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
263-365-7
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
SUB03045MIG
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
62003-27-4
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |